CLSN Celsion Corporation

1.71
+0.05  (+3%)
Previous Close 1.66
Open 1.67
Price To Book 1.94
Market Cap 36,572,485
Shares 21,387,418
Volume 183,495
Short Ratio
Av. Daily Volume 100,185
Stock charts supplied by TradingView

NewsSee all news

  1. Celsion Strengthens Its 2019 Balance Sheet with the Approval of Its Application to Sell Net Operating Losses for $2.1 Million in Non-Dilutive Funding

     $2 Million in Additional NOL Sales are Available to the Company in 2020 Funding Through the New Jersey Technology Business Tax Certificate Transfer (NOL) Program LAWRENCEVILLE, N.J., Oct. 01, 2019 (GLOBE

  2. Celsion to Present at the Chardan 3rd Annual Genetic Medicines Conference

    LAWRENCEVILLE, N.J., Sept. 30, 2019 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ:CLSN), an oncology drug-development company, announces that Michael Tardugno, Chairman, President and Chief Executive Officer and

  3. Celsion Co-sponsors Hepatocellular Carcinoma Symposium at the International Liver Cancer Association (ILCA) Annual Conference

    LAWRENCEVILLE, N.J., Sept. 23, 2019 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ:CLSN), an oncology drug-development company, announces it co-sponsored a symposium focused on hepatocellular carcinoma (HCC) at the

  4. Celsion Announces Publication of Findings from Single-Site Study in China of ThermoDox® Plus RFA in the Journal of Cancer Research and Therapeutics

    Data show overall survival improvement of 22.5 months with ThermoDox® plus RFA of 45 minutes or longer Data provides additional corroboration of ThermoDox's potential for superior efficacy when combined with a

Drug Information

Drug catalyst information is displayed when you hover over / tap on the stage bar graph.

Phase 3 interim efficacy analysis due by mid-October 2019 with second interim analysis due 1H 2020.
ThermoDox - OPTIMA
Hepatocellular carcinoma - liver cancer
Phase 1/2 data due 4Q 2019.
GEN-1 OVATION 2
Ovarian cancer
Final data released December 2015
ThermoDox - Dignity
Recurrent Chest Wall Breast Cancer (RCWBC)
Phase 1b PFS data released October 24, 2018 - PFS of 17.1 months in ITT population.
GEN-1 OVATION 1
Ovarian cancer

Latest News

  1. Celsion Strengthens Its 2019 Balance Sheet with the Approval of Its Application to Sell Net Operating Losses for $2.1 Million in Non-Dilutive Funding

     $2 Million in Additional NOL Sales are Available to the Company in 2020 Funding Through the New Jersey Technology Business Tax Certificate Transfer (NOL) Program LAWRENCEVILLE, N.J., Oct. 01, 2019 (GLOBE

  2. Celsion to Present at the Chardan 3rd Annual Genetic Medicines Conference

    LAWRENCEVILLE, N.J., Sept. 30, 2019 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ:CLSN), an oncology drug-development company, announces that Michael Tardugno, Chairman, President and Chief Executive Officer and

  3. Celsion Co-sponsors Hepatocellular Carcinoma Symposium at the International Liver Cancer Association (ILCA) Annual Conference

    LAWRENCEVILLE, N.J., Sept. 23, 2019 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ:CLSN), an oncology drug-development company, announces it co-sponsored a symposium focused on hepatocellular carcinoma (HCC) at the

  4. Celsion Announces Publication of Findings from Single-Site Study in China of ThermoDox® Plus RFA in the Journal of Cancer Research and Therapeutics

    Data show overall survival improvement of 22.5 months with ThermoDox® plus RFA of 45 minutes or longer Data provides additional corroboration of ThermoDox's potential for superior efficacy when combined with a